

VOLUME 27 · NUMBER 34 · DECEMBER 1 2009

JOURNAL OF CLINICAL ONCOLOGY


E D I T O R I A L

# Refining Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy

Harold J. Burstein and Eric P. Winer, *Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA*


SMALL, NODE-NEGATIVE, HER2-POSITIVE TUMORS

# Disease-free Survival in Patients with pT1a-b, pN0, M0, HER2-positive (HER2+) and of a Matched, HER2-negative Comparison Group (HER2-) Status



# The 5-Year Recurrence-free Survival in Patients with pT1a-b, pN0, M0 According to HER2 Status and Breast Cancer Subtype

HER2 status



Breast Cancer Subtype

